Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine, Cytarabine, and Erwinase in Relapsed/Refractory Hematologic Malignancies
NCT02718755Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2018
- Primary completion
- May 2021
- Modality
- Replacement Enzymes
01
Overview
A Phase 2 trial of Asparaginase in hematologic malignancy, sponsored by University of Texas MD Anderson Cancer Center. Planned start May 2018; status: withdrawn.
02
Drugs
Asparaginase
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT02718755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02718755.